Table 4.

Hazard ratios for clinical characteristics according to tumor subtype, breast cancer–specific mortality, adjusted for race, age at diagnosis, and date of diagnosis

AllBasal-likeLuminal ALuminal BHER2+/ERUnclassified
(n = 1,149)(n = 205)(n = 625)(n = 112)(n = 73)(n = 134)
Stage
 Stage I1.001.001.001.001.001.00
 Stage II or III2.9 (2.0–4.1)3.6 (1.4–9.1)3.0 (1.8–5.0)2.6 (0.9–7.6)3.6 (0.8–15.8)1.3 (0.6–2.9)
 Stage IV12.7 (7.4–21.7)6.4 (1.5–27.0)18.9 (7.8–46.0)11.0 (1.8–68.6)14.0 (2.5–77.5)13.1 (3.8–45.8)
Tumor size
 ≤2 cm1.001.001.001.001.001.00
 >2–5 cm2.2 (1.7–3.1)1.5 (0.8–2.9)2.5 (1.6–4.0)2.0 (0.8–4.9)2.7 (0.8–9.6)1.8 (0.8–4.1)
 >5 cm3.9 (2.7–5.9)3.2 (1.5–7.1)5.3 (2.9–9.8)3.3 (1.0–11.5)9.4 (2.2–40.1)1.0 (0.3–3.7)
Number of lymph nodes positive for malignancy
 None1.001.001.001.001.001.00
 1—22.0 (1.4–3.8)2.7 (1.4–5.4)2.2 (1.2–3.9)1.6 (0.5–5.6)2.0 (0.5–7.3)1.0 (0.3–3.6)
 3—53.7 (2.5–5.4)6.4 (2.6–15.5)4.9 (2.7–8.7)2.4 (0.7–8.3)2.5 (0.9–7.3)1.8 (0.6–5.7)
 ≥65.4 (3.9–7.5)7.2 (3.7–14.2)7.7 (4.5–13.0)5.4 (1.9–14.7)4.7 (1.6–14.4)1.9 (0.7–4.9)
Metastasis
 No1.001.001.001.001.001.00
 Yes5.8 (3.7–9.2)2.2 (0.7–7.2)8.9 (4.0–19.4)5.2 (1.1–25.3)4.5 (1.6–12.7)11.3 (3.7–34.9)